Navigation Links
Possible Cure for Rare Lymphoma Reported
Date:12/9/2007

Other blood cancer treatment advances announced at hematology meeting

SUNDAY, Dec. 9 (HealthDay News) -- Danish researchers are reporting what appears to be a cure for a rare type of lymphoma that has been regarded as incurable until now.

A complex regimen that included immunochemotherapy produced a five-year, event-free survival rate of better than 60 percent in 159 people with mantle cell lymphoma, physicians at the Rigshospitalet in Copenhagen reported Sunday at the American Society of Hematology annual meeting, in Atlanta.

The cancer was treated with six cycles of immunochemotherapy, aimed at arousing the immune system, followed by high-dose chemotherapy with stem cell support. Of the 114 people who completed treatment, 72 percent were disease-free at five years.

The report is an outstanding example of the better long-term survival rates for various kinds of blood cancers such as lymphomas being reported at the meeting, said Dr. Ruth Winter, a professor of hematology and oncology at Northwestern University in Chicago.

"All kinds of things are happening," Winter said. "These are exciting times for us all."

The advances being made "really represent a variety of different kind of approaches," Winter said, with no one thread running through the variety of trials being reported.

One piece of research represents something of a challenge to standard chemotherapy by successfully using high doses of steroids for multiple myeloma, said study author Dr. S. Vincent Rajkumar, a professor of medicine at the Mayo Clinic in Rochester, Minn.

"There is a different philosophy in this trial," Rajkumar explained. "Less can be more. For years, we have used the highest possible dose of steroids for multiple myeloma, but they have been a source of major morbidity for patients. This is the first trial in which the intensity of steroids that are used has been studied in a randomized way."

Rajkumar and his colleagues used varying doses of the steroid dexamethasone along with lenalidomide, an agent that can modify and regulate action of the immune system, to treat 445 people with multiple myeloma. One-year survival was higher in the group getting lower doses of the steroid, "96 percent survival at one year, the highest reported in any study," he said. A reduction in damaging side effects was one reason for the improvement, he added.

The approach is potentially applicable to other cancers, Rajkumar said. "As more and more drugs enter the picture, that kind of examination has to go on," he said. "As new drugs come along, can we adjust the dosage down?"

However, a study of 1,196 people treated for advanced Hodgkin's lymphoma at the University of Cologne in Germany indicated that high-dose treatment can sometimes be more effective. Patients treated with higher doses of varying chemotherapy regimens had better 10-year overall survival rates.

In another advance reported at the meeting, successful use of a form of radio-immunotherapy, using an anti-lymphoma antibody coupled with a radioactive isotope, against various forms of non-Hodgkin's lymphoma was reported by physicians at University Medical Center Utrecht, the Netherlands.

A single infusion of the combination treatment tiuxetan, prolonged by two years the time period for which there were no signs or symptoms of the cancer. Some 60,000 new cases of non-Hodgkin's lymphoma are reported in the United States each year.

And physicians from the Hospital Avicenne in Paris reported that a new drug, azacitidine, was more effective than standard chemotherapy at prolonging survival among 358 patients with high-risk myelodysplastic syndromes (MDS), which currently have no cure other than bone marrow transplantation.

More information

Learn about lymphoma from the Lymphoma Research Foundation.



SOURCES: Ruth Winter, M.D., professor, hematology, Northwestern University, Chicago; S. Vincent Rajkumar, M.D., professor, medicine, Mayo Clinic, Rochester, Minn.; Dec. 9, 2007, American Society of Hematology annual meeting, Atlanta


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Fairbank Farms Voluntarily Recalls 85% Ground Round Beef Patties Sold Fresh from Shaws Due to Possible Health Risk
2. M.D. Anderson-led team reports possible key to autoimmune disease
3. AHRQ and FDA to Collaborate in Largest Study Ever of Possible Heart Risks with ADHD Medications
4. Possible safer target for anti-clotting drugs found
5. Jefferson researchers uncover new evidence of prolactins possible role in breast cancer
6. Why it is impossible for some to just say no
7. Saving Millions of Childrens Lives Is Possible
8. Mayo Clinic Proceedings article explores possible link between obesity and viral infections
9. Mayo Clinic reports possible new therapy for patients with platinum-resistant ovarian cancer
10. Help for California Fire Evacuees Possible Through Partnership for Prescription Assistance
11. Mayo Clinic study points to a possible biomarker for colon cancer in people 50 and under
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Possible Cure for Rare Lymphoma Reported
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Bay Area Lyme Foundation , collaborating ... for Tick Borne Illness , Harvard Medical School ... Medicine, University of California, Berkeley, and the Veterans ... finalists of Lyme Innovation , the first ... scientists, clinicians, researchers, entrepreneurs, and investors from several ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: ... and sells medical devices and wearable sleep respiratory products ... cooperation agreement with Hongyuan Supply Chain Management Co., Ltd. ... 20, 2016, to develop Dehaier,s new Internet medical technology ... will leverage Hongyuan Supply Chain,s sales platform to reach ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
Breaking Medicine Technology: